CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 21, 2006--SkinMedica, Inc., announced today the positive outcome of two Phase III clinical trials evaluating Desonate (desonide) HydroGel 0.05%, a low-potency topical steroid formulated in a proprietary alcohol-free, aqueous gel delivery vehicle to treat atopic dermatitis. SkinMedica, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing products that improve the appearance of skin and treat dermatologic conditions and diseases.
